Literature DB >> 28361073

Is there a benefit to locally consolidative therapy for oligometastatic non-small cell lung cancer?

Lauren Boreta1, Sue S Yom1.   

Abstract

Entities:  

Year:  2017        PMID： 28361073      PMCID： PMC5360618          DOI： 10.21037/atm.2017.01.21

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  21 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

Review 2.  The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors: What do we know and where are we going?

Authors:  Julian C Hong; Joseph K Salama
Journal:  Cancer Treat Rev       Date:  2016-11-10       Impact factor: 12.111

3.  Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.

Authors:  Puneeth Iyengar; Brian D Kavanagh; Zabi Wardak; Irma Smith; Chul Ahn; David E Gerber; Jonathan Dowell; Randall Hughes; Ramzi Abdulrahman; D Ross Camidge; Laurie E Gaspar; Robert C Doebele; Paul A Bunn; Hak Choy; Robert Timmerman
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

Review 4.  Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.

Authors:  Allison Ashworth; George Rodrigues; Gabriel Boldt; David Palma
Journal:  Lung Cancer       Date:  2013-08-20       Impact factor: 5.705

Review 5.  Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer.

Authors: 
Journal:  Cochrane Database Syst Rev       Date:  2010-05-12

6.  Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).

Authors:  Dirk De Ruysscher; Rinus Wanders; Angela van Baardwijk; Anne-Marie C Dingemans; Bart Reymen; Ruud Houben; Gerben Bootsma; Cordula Pitz; Linda van Eijsden; Wiel Geraedts; Brigitta G Baumert; Philippe Lambin
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

7.  Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.

Authors:  William J Magnuson; Jacky T Yeung; Paul D Guillod; Scott N Gettinger; James B Yu; Veronica L Chiang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-02       Impact factor: 7.038

8.  Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference.

Authors:  Z U Rahman; D K Frye; T L Smith; L Asmar; R L Theriault; A U Buzdar; G N Hortobagyi
Journal:  Cancer       Date:  1999-01-01       Impact factor: 6.860

9.  Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Authors:  Daniel R Gomez; George R Blumenschein; J Jack Lee; Mike Hernandez; Rong Ye; D Ross Camidge; Robert C Doebele; Ferdinandos Skoulidis; Laurie E Gaspar; Don L Gibbons; Jose A Karam; Brian D Kavanagh; Chad Tang; Ritsuko Komaki; Alexander V Louie; David A Palma; Anne S Tsao; Boris Sepesi; William N William; Jianjun Zhang; Qiuling Shi; Xin Shelley Wang; Stephen G Swisher; John V Heymach
Journal:  Lancet Oncol       Date:  2016-10-24       Impact factor: 41.316

10.  Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy.

Authors:  Christina Bluemel; Fraenze Linke; Ken Herrmann; Iva Simunovic; Matthias Eiber; Christian Kestler; Andreas K Buck; Andreas Schirbel; Thorsten A Bley; Hans-Juergen Wester; Daniel Vergho; Axel Becker
Journal:  EJNMMI Res       Date:  2016-10-26       Impact factor: 3.138
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.